ZA201206869B - Parenteral dosage form releasing aromatase inhibitors and gestagens to treat endometriosis - Google Patents

Parenteral dosage form releasing aromatase inhibitors and gestagens to treat endometriosis

Info

Publication number
ZA201206869B
ZA201206869B ZA2012/06869A ZA201206869A ZA201206869B ZA 201206869 B ZA201206869 B ZA 201206869B ZA 2012/06869 A ZA2012/06869 A ZA 2012/06869A ZA 201206869 A ZA201206869 A ZA 201206869A ZA 201206869 B ZA201206869 B ZA 201206869B
Authority
ZA
South Africa
Prior art keywords
gestagens
dosage form
aromatase inhibitors
parenteral dosage
treat endometriosis
Prior art date
Application number
ZA2012/06869A
Other languages
English (en)
Inventor
Henrikka Korolainen
Harri Jukarainen
Christine Talling
Heinz Schmitz
Rudolf Knauthe
Arto Pakkalin
Original Assignee
Kocide Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44021822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201206869(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kocide Llc filed Critical Kocide Llc
Publication of ZA201206869B publication Critical patent/ZA201206869B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA2012/06869A 2010-03-31 2012-09-13 Parenteral dosage form releasing aromatase inhibitors and gestagens to treat endometriosis ZA201206869B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010003494A DE102010003494A1 (de) 2010-03-31 2010-03-31 Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
PCT/EP2011/054737 WO2011120925A1 (de) 2010-03-31 2011-03-28 Parenterale arzneiform, die aromatasehemmer und gestagene freisetzt, für die behandlung von endometriose

Publications (1)

Publication Number Publication Date
ZA201206869B true ZA201206869B (en) 2016-01-27

Family

ID=44021822

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/06869A ZA201206869B (en) 2010-03-31 2012-09-13 Parenteral dosage form releasing aromatase inhibitors and gestagens to treat endometriosis

Country Status (41)

Country Link
US (2) US20130131027A1 (enExample)
EP (1) EP2552404B1 (enExample)
JP (2) JP6012048B2 (enExample)
KR (1) KR20130010047A (enExample)
CN (1) CN103002873B (enExample)
AR (1) AR080861A1 (enExample)
AU (1) AU2011234587B2 (enExample)
BR (1) BR112012024739A2 (enExample)
CA (1) CA2794790A1 (enExample)
CL (1) CL2012002722A1 (enExample)
CO (1) CO6630125A2 (enExample)
CR (1) CR20120493A (enExample)
CU (1) CU20120145A7 (enExample)
CY (1) CY1116187T1 (enExample)
DE (1) DE102010003494A1 (enExample)
DK (1) DK2552404T3 (enExample)
DO (1) DOP2012000255A (enExample)
EA (1) EA025582B1 (enExample)
EC (1) ECSP12012176A (enExample)
ES (1) ES2533101T3 (enExample)
GT (1) GT201200267A (enExample)
HR (1) HRP20150294T1 (enExample)
IL (1) IL222056A (enExample)
MA (1) MA34099B1 (enExample)
ME (1) ME02159B (enExample)
MX (1) MX2012011329A (enExample)
MY (1) MY160353A (enExample)
NZ (1) NZ602698A (enExample)
PE (1) PE20130524A1 (enExample)
PH (1) PH12012501944A1 (enExample)
PL (1) PL2552404T3 (enExample)
PT (1) PT2552404E (enExample)
RS (1) RS53876B1 (enExample)
SG (1) SG184111A1 (enExample)
SI (1) SI2552404T1 (enExample)
TN (1) TN2012000468A1 (enExample)
TW (2) TWI576107B (enExample)
UA (1) UA109655C2 (enExample)
UY (1) UY33303A (enExample)
WO (1) WO2011120925A1 (enExample)
ZA (1) ZA201206869B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
JP2018515796A (ja) * 2015-05-27 2018-06-14 クエスト ダイアグノスティックス インヴェストメンツ エルエルシー マイクロサンプリングデバイスにより抽出された被分析物の質量分析による定量のための方法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
PE20181214A1 (es) * 2015-12-21 2018-07-24 Bayer Oy Metodo para fabricar un dispositivo para la administracion de farmacos y un dispositivo para la administracion de farmacos fabricado segun el metodo
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CN109248166A (zh) * 2017-07-13 2019-01-22 国家卫生计生委科学技术研究所 阿那曲唑储库型阴道环的制备及应用
US11529308B2 (en) 2019-06-21 2022-12-20 The Population Council, Inc. System for providing birth control
US10918649B2 (en) 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
US20240122885A1 (en) * 2021-02-12 2024-04-18 The Regents Of The University Of California Endometriosis-Related Methods and Compositions
WO2023163914A1 (en) * 2022-02-22 2023-08-31 Celanese Eva Performance Polymers Llc Intravaginal ring device for the delivery of aromatase inhibitor
CN115804762B (zh) * 2022-12-20 2024-05-31 浙江大学 一种巨噬细胞膜包覆的异位子宫内膜靶向纳米粒、制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
JP2602456B2 (ja) * 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
FI95768C (fi) * 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US7744916B2 (en) * 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
FI20000572A7 (fi) * 2000-03-13 2001-09-14 Schering Oy Implantaattien asettamiseen tarkoitettu laite
EP1377298B1 (en) * 2001-01-26 2006-08-30 Pfizer Italia S.r.l. Exemestane for treating hormono-dependent disorders
GB0120147D0 (en) * 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017974A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
GB0320238D0 (en) * 2003-08-29 2003-10-01 Medical Res Council Treatment of disease
US20050101579A1 (en) * 2003-11-06 2005-05-12 Shippen Eugene R. Endometriosis treatment protocol
AR066166A1 (es) * 2007-09-21 2009-07-29 Organon Nv Sistema de suministro de droga
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
US20110033519A1 (en) 2009-08-07 2011-02-10 Leong Madeline Device with Aromatase Inhibitor for the Treatment and Prevention of Uterine Fibroids and Method of Use

Also Published As

Publication number Publication date
TW201632184A (zh) 2016-09-16
JP2013523683A (ja) 2013-06-17
EP2552404A1 (de) 2013-02-06
CN103002873A (zh) 2013-03-27
PH12012501944A1 (en) 2017-01-06
ECSP12012176A (es) 2012-10-30
CY1116187T1 (el) 2017-02-08
SG184111A1 (en) 2012-10-30
ME02159B (me) 2015-10-20
WO2011120925A1 (de) 2011-10-06
MY160353A (en) 2017-02-28
EA201201358A1 (ru) 2013-04-30
CA2794790A1 (en) 2011-10-06
UA109655C2 (uk) 2015-09-25
BR112012024739A2 (pt) 2016-06-07
NZ602698A (en) 2014-08-29
UY33303A (es) 2011-10-31
PT2552404E (pt) 2015-03-30
ES2533101T3 (es) 2015-04-07
US20130131027A1 (en) 2013-05-23
TWI576107B (zh) 2017-04-01
HK1179531A1 (en) 2013-10-04
AR080861A1 (es) 2012-05-16
US20150359802A1 (en) 2015-12-17
TW201201799A (en) 2012-01-16
CR20120493A (es) 2012-11-22
CL2012002722A1 (es) 2013-01-18
RS53876B1 (sr) 2015-08-31
MX2012011329A (es) 2012-11-30
SI2552404T1 (sl) 2015-04-30
CN103002873B (zh) 2015-02-18
CO6630125A2 (es) 2013-03-01
DOP2012000255A (es) 2013-04-30
TN2012000468A1 (en) 2014-01-30
PL2552404T3 (pl) 2015-05-29
GT201200267A (es) 2014-06-04
IL222056A (en) 2016-03-31
EP2552404B1 (de) 2015-01-21
MA34099B1 (fr) 2013-03-05
HRP20150294T1 (hr) 2015-06-19
PE20130524A1 (es) 2013-04-26
EA025582B1 (ru) 2017-01-30
AU2011234587A1 (en) 2012-10-25
JP2016164200A (ja) 2016-09-08
CU20120145A7 (es) 2013-05-31
AU2011234587B2 (en) 2015-07-09
KR20130010047A (ko) 2013-01-24
DK2552404T3 (en) 2015-03-30
JP6012048B2 (ja) 2016-10-25
DE102010003494A1 (de) 2011-10-06

Similar Documents

Publication Publication Date Title
IL222056A (en) Intravenous dosage form releasing aromatase inhibitors and gastrogens to treat endometrial disease
SG10201500048SA (en) Compositions and methods for treating glioblastoma gbm
EP2739288A4 (en) PROGESTERONE-CONTAINING ORAL PHARMACEUTICAL FORMS AND RELEVANT PROCEDURES
IL237849A0 (en) ret suppressors and their uses
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
EP2655334A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
EP2687155A4 (en) HUMIDITY MEASURING DEVICE AND BODY MOISTURE MEASURING DEVICE
IL235939A0 (en) Methods for treating overweight and obesity
IL219279A0 (en) Corticosteroid and anti-cd56-maytansinoid conjugate dosing regimens and uses thereof
IL230917A0 (en) 1dyrk inhibitors and uses thereof
ZA201300693B (en) Tube-feed packages and methods for using same
EP2534145A4 (en) THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING THE INHIBITION OF ALLOSTERIC KINASE
IL234829A0 (en) Methods and preparations for treating inflammation
IL237321A0 (en) ddr2 inhibitors and pharmaceutical preparations containing them
PL2917231T3 (pl) Lipopeptydy do stosowania w leczeniu chorób wątroby i chorób sercowo-naczyniowych
EP2574172A4 (en) MATERIALS AND METHOD FOR TREATING INFLAMMATION
PL2812323T3 (pl) Pochodne tetrahydro-chinazolinonowe jako inhibitory tank i parp
EP2590674A4 (en) COMPOSITIONS AND METHODS FOR INFLUENZA TREATMENT
ZA201309365B (en) Glioblastoma inhibiting compounds and their use
GB201013701D0 (en) A method of treating testosterone deficiency and pharmaceutical compositions for use in such a method
SG10201510568WA (en) Novel 19-nor-steroids and their use for treating progesterone-dependent conditions
PL2542241T3 (pl) Sposoby i kompozycje do leczenia lub zapobiegania objawom wahań hormonalnych
EP2616057A4 (en) COMBINATION OF B-RAF AND VEGFR INHIBITORS
EP3406242C0 (en) TLR4 ANTAGONIST FOR USE IN THE TREATMENT OF INCREASED PLASMA AMMONIA LEVELS
PL2606032T3 (pl) Kompozycja i sposoby terapii glejakaep